Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children Ages 4 to 17 Years
Phase of Trial: Phase III
Latest Information Update: 14 Dec 2017
At a glance
- Drugs AR 101 (Primary)
- Indications Peanut hypersensitivity
- Focus Adverse reactions; Registrational
- Acronyms RAMSES
- Sponsors Aimmune Therapeutics
- 08 Nov 2017 Planned number of patients changed from 440 to 500.
- 08 Aug 2017 According to an Aimmune Therapeutics media release, this trial is expected to support regulatory filings in the USA in late 2018.
- 02 May 2017 Status changed from not yet recruiting to recruiting.